There is a new medicine against breast cancer

The results of clinical trials of the drug Afinitor (everolimus) have shown that the drug is able to delay the onset of relapses in patients with breast cancer at later stages. It offers a completely new approach to the treatment of the disease, based on the effects of targeted therapy.

Targeted treatment - a new direction in the field of molecular biology in oncology. Until recently, the treatment of patients with metastatic hormone-   breast cancer   It carried out exclusively by endocrine. He had one drawback - most of the "heavy" patients who initially respond to hormones, eventually becoming resistant to them.

The results showed that the new drug in combination with endocrine therapy by more than 2-fold increased relapse-free period of the disease. In addition, a targeted effect on onkoobrazovanie its progression slowed by 57% compared with traditional endocrine therapy. These data provided important scientific breakthrough in the treatment of hormone-sensitive breast cancer.

"Today everolimus - is the only drug that can increase the effectiveness of endocrine therapy in" heavy "patients. We have great expectations from the "point" action on the causes of carcinogenesis, as there is strong evidence that it prolongs the life of sick women, "- commented Irina Poddubnaya, corresponding member of RAMS, MD, Professor, Head of the Department of Oncology of the Russian Medical Academy of Postgraduate Education Health Ministry of Russia at the Russian Cancer Research Center. ak. NN Blokhin.

For reference:
Everolimus is included in the list of vital and essential medicines in 2012.

Treatment and prevention

Go back to the main page